Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Capital Expenditures of $258000.0 for Q1 2026, up 104.94% on a QoQ basis from -$5.2 million in Q4 2025, and down 85.92% year-over-year from $1.8 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $258000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 85.92% year-over-year to $258000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 117.74% YoY) and the FY2024 annual result came in at $13.7 million, up 14.55% from the prior year.
- Capital Expenditures was $258000.0 for Q1 2026 at Recursion Pharmaceuticals, up from -$5.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $12.0 million in Q4 2023 and bottomed at -$6.1 million in Q2 2024.
- A 5-year average of $1.6 million and a median of $258000.0 in 2026 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 2976.79% — and 2024, when it surged 197566.67%.
- Recursion Pharmaceuticals' Capital Expenditures stood at -$2.5 million in 2022, then jumped by 577.82% to $12.0 million in 2023, then plunged by 89.14% to $1.3 million in 2024, then tumbled by 502.54% to -$5.2 million in 2025, then jumped by 104.94% to $258000.0 in 2026.
- Business Quant data shows RXRX's Capital Expenditures at $258000.0 in Q1 2026, -$5.2 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | 258,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258,000.00 |
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | -5.23 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Jun 30, 2024 | -6.10 Mn |
| Jun 30, 2024 | -6.10 Mn |
| Mar 31, 2024 | 6.65 Mn |
| Mar 31, 2024 | 6.65 Mn |
| Dec 31, 2023 | 11.96 Mn |
| Dec 31, 2023 | 11.96 Mn |